Iterum Therapeutics Regains Nasdaq Compliance
Iterum Therapeutics Regains Nasdaq Compliance
Iterum Therapeutics plc (NASDAQ:ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured and that the Company is in compliance with applicable continued listing requirements.
Iterum therapeutics plc（纳斯达克：ITRM），（以下简称“公司”），是一家专注于提供新一代口服和静脉注射抗生素用于治疗由多重耐药病原体引起的感染的公司，适用于社区和医院环境，今天宣布收到纳斯达克证券市场有限责任公司的上市资格工作人员的书面通知，告知公司其在上市规则5550(b)下的缺陷已得到纠正，并且公司符合适用的持续上市要求。
Based on the foregoing, the previously scheduled Nasdaq hearing before the Hearings Panel on November 21, has been cancelled. The Company will continue to be traded on The Nasdaq Capital Market.
基于上述原因，原定于11月21日的纳斯达克听证会已被取消。公司将继续在纳斯达克资本市场交易。
